mental health issues Archives

In Depth 12 Sep 2024

New treatments being developed for schizophrenia

Explore the latest strides in schizophrenia treatment development as 2024 heralds a pivotal year, with promising collaborations and trials.

September 12, 2024

In Depth 13 May 2024

New antidepressants: tackling treatment resistant depression

Take a look at how new antidepressants can more effectively tackle treatment resistant depression compared to more traditional treatments.

May 13, 2024 - 11 minutesmins - By Willow Shah-Neville

In Depth 13 Mar 2024

From LSD to healing minds: Where are we standing in psychedelic drug development?

Delve into the growing sector of psychedelic drug development to find out where we are coming from, and where we are standing in the field.

March 13, 2024 - 13 minutesmins - By Jules Adam

Best in Biotech 30 Jan 2024

Navigating German biotech: 13 key players to know

The German biotech ecosystem is well established despite the challenges it is facing. Discover thirteen key Germany-based biotech companies.

January 30, 2024 - 18 minutesmins - By Jules Adam

Best in Biotech 25 Jan 2024

Eight mental health biotech companies trying to make a difference to people’s lives

Take a closer look at eight mental health companies developing therapies that could make a different to people with mental illnesses.

January 25, 2024 - 11 minutesmins - By Willow Shah-Neville

Best in Biotech 16 Jan 2024

Five biotech companies taking Florida by storm

Check out five of the top Florida companies taking the state’s biotech industry by storm with their innovative technologies.

January 16, 2024 - 6 minutesmins - By Willow Shah-Neville

News and Trends 2 May 2023

Schizophrenia injection gets FDA approval

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and MedinCell have announced the U.S. Food and Drug Administration (FDA) has approved UZEDY (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults. UZEDY is the first subcutaneous, long-acting formulation of risperidone that utilizes SteadyTeq, a copolymer technology proprietary to MedinCell that controls […]

May 2, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 21 Mar 2023

Karuna Therapeutics sees positive schizophrenia trial results

Karuna Therapeutics, Inc. has announced positive topline results from its phase 3 EMERGENT-3 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium) in adults with schizophrenia. The trial met its primary endpoint, with KarXT demonstrating a statistically significant and clinically meaningful 8.4-point reduction in positive and negative syndrome scale (PANSS) […]

March 21, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 21 Mar 2023

Campbell Neurosciences creates saliva-based test for suicidal thoughts

Therapeutic Solutions International (TSOI) has announced that its spin-off biotech company, Campbell Neurosciences, Inc., obtained successful validation of its suicidal ideation predictive test using a saliva-based system. Previously, the company reported successful stratification of suicidal tendencies using a proprietary blood-based biomarker. In the trial, the company previously assessed levels of the inflammatory marker in 10 […]

March 21, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 16 Feb 2023

Newron reports ‘striking’ schizophrenia study results

Newron Pharmaceuticals S.p.A. has announced what it says are ‘very exciting new results’ from the first 100 randomized patients who have completed one year of treatment in its study of evenamide as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe treatment-resistant schizophrenia (TRS) not responding to their current antipsychotic medication. […]

February 16, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 3 Jan 2023

Newron announces interim results from treatment-resistant schizophrenia trial

Newron Pharmaceuticals S.p.A. has announced what it says are “very compelling new results” from the first 100 enrolled patients to have reached the six-month timepoint in its international study of evenamide as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe treatment-resistant schizophrenia (TRS), who were not responding to their current […]

January 3, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

Potential new lead compounds for treatment of depression and anxiety disorders

Currently, various classes of drugs are available for the treatment of mental illnesses – such as depression and anxiety disorders. However, although these drugs have benefits, they can also be associated with adverse side-effects. A research group has conducted a study to identify new drugs that could potentially be used for the treatment of neuropsychiatric […]

November 15, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

mental health issues

New treatments being developed for schizophrenia

New antidepressants: tackling treatment resistant depression

From LSD to healing minds: Where are we standing in psychedelic drug development?

Navigating German biotech: 13 key players to know

Eight mental health biotech companies trying to make a difference to people’s lives

Five biotech companies taking Florida by storm

Schizophrenia injection gets FDA approval

Karuna Therapeutics sees positive schizophrenia trial results

Campbell Neurosciences creates saliva-based test for suicidal thoughts

Newron reports ‘striking’ schizophrenia study results

Newron announces interim results from treatment-resistant schizophrenia trial

Potential new lead compounds for treatment of depression and anxiety disorders

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!